The methylation biomarkers with the highest level of validation in bodily fluid are SHOX2 and SEPT9. In lung cancer, the reliability of SHOX2 as a biomarker has been confirmed in bronchial aspirates and plasma [11–14]. This evidence concerns the gene SHOX2 and lung cancer.